Hanker et al. demonstrated co-occurrence of gain-of-function mutations in various HER2 mutations and HER3 E928G missense mutation, resulting in subsequent HER-signaling and breast cancer growth [21]. This evidence concerns the gene ERBB2 and breast cancer.